Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer

(701121)

<table>
<thead>
<tr>
<th>Medical Benefit</th>
<th>Effective Date: 01/01/15</th>
<th>Next Review Date: 11/18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preauthorization</td>
<td>No</td>
<td>Review Dates: 09/09, 03/10, 01/11, 01/12, 01/13, 01/14, 11/14, 11/15, 11/16, 11/17</td>
</tr>
</tbody>
</table>

**Preauthorization is not required.**

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered.

### Populations

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals:</td>
<td></td>
<td>Relevant outcomes include:</td>
</tr>
<tr>
<td>• With suspected prostate cancer</td>
<td>Interventions of interest are:</td>
<td>Comparators of interest are:</td>
</tr>
<tr>
<td></td>
<td>• Initial saturation biopsy</td>
<td>• Standard biopsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Relevant outcomes include:</td>
</tr>
<tr>
<td>Individuals:</td>
<td></td>
<td>Relevant outcomes include:</td>
</tr>
<tr>
<td>• With suspected prostate cancer</td>
<td>Interventions of interest are:</td>
<td>Comparators of interest are:</td>
</tr>
<tr>
<td></td>
<td>• Repeat saturation biopsy</td>
<td>• Standard biopsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Relevant outcomes include:</td>
</tr>
<tr>
<td>Individuals:</td>
<td></td>
<td>Relevant outcomes include:</td>
</tr>
<tr>
<td>• With prostate cancer who are candidates for active surveillance</td>
<td>Interventions of interest are:</td>
<td>Comparators of interest are:</td>
</tr>
<tr>
<td></td>
<td>• Saturation biopsy</td>
<td>• Standard biopsy</td>
</tr>
</tbody>
</table>

### Description

Saturation biopsy of the prostate, in which more cores are obtained than by standard biopsy protocol, has been proposed in the diagnosis (for initial or repeat biopsy), staging, and management of patients with prostate cancer.

### Summary of Evidence

For individuals who have suspected prostate cancer who receive initial saturation biopsy, the evidence includes randomized controlled trials (RCTs), observational studies and systematic reviews. Relevant outcomes are overall survival, disease-specific survival, test accuracy, and treatment-related morbidity. A 2013 systematic review found higher rates of cancer detection with saturation biopsy than with extended biopsy overall, but, in the subgroup of men with prostate-specific antigen levels less than 10 ng/mL, the degree of difference was small and possibly not clinically significant. Health outcomes (e.g., survival rate) were not reported. Although several studies were published after the systematic review, none showed that initial saturation biopsy improves the
detection of clinically significant cancers and none reported progression or survival outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have suspected prostate cancer who receive repeat saturation biopsy, the evidence includes observational studies and a systematic review. Relevant outcomes are overall survival, disease-specific survival, test accuracy, and treatment-related morbidity. Several studies have compared saturation and standard prostate biopsies in the repeat biopsy setting and have found significantly higher detection rates with saturation biopsy. However, at least one study found that about one-third of the positive findings with saturation biopsy were clinically insignificant cancers. Moreover, studies of saturation biopsy as the repeat prostate biopsy strategy focused on cancer detection rates and did not report health outcomes (e.g., progression or survival). Evidence is lacking as to whether saturation biopsy leads to improved health outcomes, including the possibility of detecting clinically insignificant cancers, which could lead to unnecessary treatment. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have prostate cancer and are candidates for active surveillance who receive saturation biopsy, the evidence includes two nonrandomized comparative studies. Relevant outcomes are overall survival, disease-specific survival, test accuracy, and treatment-related morbidity. Both studies retrospectively compared standard biopsy with saturation biopsy for selecting patients for active surveillance; neither found that saturation biopsy improved the ability to select patients. In one study, biopsy method was not a significant predictor of upstaging and, in the other study, biopsy method was not significantly associated with selecting patients with a high Gleason score. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy

Saturation biopsy is considered **investigational** in the diagnosis, staging, and management of prostate cancer.

Policy Guidelines

Saturation biopsy is generally considered as obtaining more than 20 biopsy tissue cores from the prostate in a systematic manner; it is occasionally defined as obtaining more than 18 biopsy tissue cores.

Background

*Prostate Cancer*

Prostate cancer is common and is the second leading cause of cancer-related deaths in men in the United States.

Diagnosis

The diagnosis of prostate cancer is made by biopsy of the prostate gland. The approach to biopsy has changed over time, especially with the advent of prostate-specific antigen screening programs that identify cancer in prostates that are normal to palpation and to transrectal ultrasound. For patients with an elevated prostate-specific antigen level but with a normal biopsy, questions exist about subsequent evaluation, because repeat biopsy specimens may be positive for cancer in a substantial percentage of patients.

In the early 1990s, use of sextant biopsies involving six random, evenly distributed biopsies became the standard approach to diagnosis prostate cancer. In the late 1990s, as studies showed high false-negative rates for this strategy (missed cancers), approaches were developed to increase the total number of biopsies and to change the location of the biopsies. While there is disagreement about the optimal strategy, most would agree that initial prostate biopsy strategies should include at least 10 to 14 cores. Additional concerns have been raised
about drawing conclusions about the stage (grade) of prostate cancer based on limited biopsy specimens. Use of multiple biopsies has also been discussed as an approach to identify tumors that may be eligible for subtotal cryoablation therapy.

At present, many practitioners use a 12- to 14-core “extended” biopsy strategy for patients undergoing initial biopsy. This extended biopsy is done in an office setting and allows for more extensive sampling of the lateral peripheral zone; sampling of the lateral horn might increase the cancer detection rate by approximately 25%.

Another approach to increase the number of biopsy tissue cores is “saturation” biopsy. In general, saturation biopsy is considered as more than 20 cores taken from the prostate, with improved sampling of the anterior zones of the gland, which may be undersampled in standard peripheral zone biopsy strategies and might lead to missed cancers. Saturation biopsy might be performed transrectally or transperineally; the transperineal approach is generally performed as a stereotactic template-guided procedure with general anesthesia.

### Surveillance

In addition to diagnosis of prostate cancer, some have suggested that saturation biopsy could be a part of active surveillance (a treatment approach for men with prostate cancer that involves surveillance with PSA, digital rectal exam, and routine prostate biopsies in men whose cancers are small and expected to behave indolently). Saturation biopsy has the potential to identify tumor grade more accurately than standard biopsy.

### Regulatory Status

Saturation biopsy is a surgical procedure and, as such, is not subject to regulation by the U.S. Food and Drug Administration.

### Related Protocol

**Whole Gland Cryoablation of Prostate Cancer**

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

### References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.


